Oragenics To Participate at the World Vaccine Congress Washington 2022
Oragenics, Inc. (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.
Using AI in the Arts To Promote COVID-19 Vaccines
Sure, it is fun to see an avatar simulate your body movements in real time, but the interactive augmented reality art installation making its way around campus has a serious aim: educating participants about how COVID-19 impacts health and encouraging vaccination.
Oragenics Extends Collaboration To Develop Vaccines Against Future Variants of Coronaviruses
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
UF Researchers Help Develop Highly Accurate, 30-Second Coronavirus Test
Researchers at the University of Florida, have helped developed a COVID-19 testing device that can detect coronavirus infection in as little as 30 seconds as sensitively and accurately as a PCR, or polymerase chain reaction test, the gold standard of testing.
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine
New COVID Test Can Quickly Detect Variants
University of Florida researchers have invented a test that can determine within 10-15 minutes whether patients test positive for COVID and, if so, which of the five known variants of concern they have.
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
Oragenics, Inc. announced it has entered into an agreement with KBI Biopharma, Inc. for the process transfer, process optimization, and cGMP manufacturing of Oragenics’s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line.
Covid-19 Nasal Vaccine Produces Antibodies, Cuts Viral Load
Tests with lab animals show a vaccine given as a nasal spray produces high antibody volumes against SARS-CoV-2 infections and reduces viral loads. Results of tests by biotechnology companies Oragenics Inc., a Sid Martin Biotech alum located in Tampa, and Inspirevax in Laval, Quebec, with National Research Council of Canada, appear on the bioRxiv pre-publication server, and are not yet peer-reviewed.
Endemic COVID-19 Could Be 1 to 10 Years Away
If you donned your mask today and felt a primal urge to yell “When will this pandemic END-emic already?!” take heart. You are not alone.
Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine
UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
